www.newsmax.com
Novo Nordisk Strikes US Medicare Price Deal
Novo Nordisk said Wednesday it had agreed to a lower price under the U.S. Medicare scheme for semaglutide, the active ingredient in its key drugs Ozempic and Wegovy, in a deal that some analysts said sounded less onerous than feared.